Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2007

Compendia Bioscience Signs Oncomine Licensing Agreement with AstraZeneca

  • Compendia Bioscience licensed Oncomine™, the company’s compendium of oncology gene expression profiles and analysis tools, to AstraZeneca. The firm will conduct a year-long pilot to evaluate the long-term role of this product in its cancer research programs.

    This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition (OCM), a value-added product extension of Oncomine that reportedly combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »